20-Hydroxyecdysone activates the protective arm of the renin angiotensin system via Mas receptor
Open accessAbstract
20-Hydroxyecdysone (20E) is a steroid hormone that plays a key role in insect development through nuclear ecdysone receptors (EcRs) and at least one membrane GPCR receptor (DopEcR) and displays numerous pharmacological effects in mammals. However, its mechanism of action is still debated, involving either an unidentified GPCR or the estrogen ERβ receptor. The goal of our study was to better understand 20E mechanism of action. A mouse myoblast cell line (C2C12) and the gene expression of myostatin (a negative regulator of muscle growth) was used as a reporter system of anabolic activity. Experiments using protein-bound 20E established the involvement of a membrane receptor. 20E-like effects were also observed with Angiotensin-(1-7), the endogenous ligand of Mas. Additionally, the effect on myostatin gene expression was abolished by Mas receptor knock-down using small interfering RNA (siRNA) or pharmacological inhibitors. 17β-Estradiol (E2) also inhibited myostatin gene expression, but protein-bound E2 was inactive, and E2 activity was not abolished by angiotensin-(1-7) antagonists. A mechanism involving cooperation between Mas receptor and a membrane-bound palmitoylated estrogen receptor is proposed. The possibility to activate the Mas receptor with a safe steroid molecule is consistent with the pleiotropic pharmacological effects of ecdysteroids in mammals and indeed this mechanism may explain the close similarity between angiotensin-(1-7) and 20E effects. Our findings open a lot of possible therapeutic developments by stimulating the protective arm of the renin-angiotensin-aldosterone system (RAAS) with 20E.
AI snapshot
Written from the paper’s full text.
TL;DR
20-Hydroxyecdysone (20E) inhibits myostatin gene expression and stimulates protein synthesis in C2C12 myotubes through a membrane-initiated mechanism involving the Mas receptor, the angiotensin-(1-7) receptor. The authors propose that 20E activates the protective arm of the renin-angiotensin system via Mas, with cooperation from a non-nuclear membrane estrogen receptor.
Key findings
- 20E increased de novo protein synthesis in differentiated C2C12 myotubes, with a maximal effect of +27% at 5 µM (p < 0.001); IGF-1 (100 ng/mL) increased incorporation by +20% (p < 0.001).
- 20E dose-dependently inhibited myostatin gene expression, reaching significance from 0.5 µM; the membrane-impermeable 20E-HSA conjugate retained activity similar to free 20E at 10 µM 20E-equivalents.
- Mas antagonists A1 and A779, and MAS siRNA knockdown, abolished the inhibitory effects of both 20E and angiotensin-(1-7) on myostatin expression, while IGF-1 effects were unchanged.
- 20E did not bind AR, ERα, or ERβ up to 100 µM, and a screen of 45 GPCRs and 5 nuclear receptors at 10 µM 20E was negative; E2 inhibited myostatin from 0.1 to 1 µM, but E2-CMO-BSA was inactive (−8%, ns) and E2 activity was not blocked by A779.
Methods
- C2C12 mouse myoblast cells were differentiated into myotubes and used for protein synthesis assays ([3H]-leucine incorporation) and qRT-PCR of myostatin and MAS.
- Treatments included 20E, IGF-1, angiotensin-(1-7), Mas antagonists A1/A779, MAS siRNA, 17β-estradiol (E2), E2-CMO, E2-CMO-BSA, and 17α-estradiol.
- Binding studies used radioligand competition for AR, ERα, ERβ, and GR up to 100 µM 20E, plus a fixed-concentration screen of 45 GPCRs and 5 nuclear receptors; statistics used ANOVA/Dunnett, Kruskal-Wallis/Dunn, t-test, or Mann-Whitney as appropriate.
Limitations
- The paper states that the results do not unambiguously identify the primary target and that the specific membrane estrogen receptor form involved remains open.
- The paper states that demonstrating the proposed functional Mas–estrogen receptor association will require membrane fractionation combined with immunoprecipitation techniques.
- The paper notes that clinical evidence for 20E effectiveness in humans remains limited; evident from the text, the experimental work is in vitro using the C2C12 cell line, with no in vivo or human data reported here.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
0 of 15 cited sources checked · 0 supported · 0 flagged
- Findingown data
The maximal 20E effect on protein synthesis is +27% (p<0.001) at 5 μM.
“The maximal effect (+ 27 %; p < 0.001) was measured with 5 μM of 20E”
Quote in the paperNot a substantial claim - Findingown data
The inhibition of myostatin gene expression by 20E reaches significance from 0.5 μM.
“This inhibition reached significance from 0.5 µM 20E (Fig. 1B).”
Quote in the paperNot a substantial claim - Findingown data
20E treatment of C2C12 myotubes causes a dose-dependent increase in de novo protein synthesis versus untreated conditions.
“A dose-dependent increase in protein synthesis was observed in response to 20E treatment of C2C12 myotubes versus untreated conditions (Fig. 1A).”
Quote in the paperNot a substantial claim - Findingown data
10 μM 20E is notably less efficient (+11%, ns) than 5 μM for protein synthesis.
“while a treatment with a higher concentration of 20E (10 μM) appeared to be notably less efficient (+11%, ns) than the previous concentration tested.”
Quote in the paperNot a substantial claim - Findingown data
The 20E effect on protein synthesis is significant from 0.5 μM to 5 μM.
“20E effect was significant from 0.5 μM to 5 μM.”
Quote in the paperNot a substantial claim
- Findingown data
20E dose-dependently and partially inhibits myostatin gene expression in C2C12 cells at concentrations between 0.001 and 10 μM.
“A dose-dependent and partial inhibition of myostatin gene expression was observed in response to 20E treatment at concentrations comprised between 0.001 and 10 µM.”
Quote in the paperSubstantial claim - Findingown data
IGF-1 (100 ng/mL) significantly inhibits myostatin gene expression to 57% of untreated control cells (p<0.001).
“IGF-1 (100 ng/mL) used as a positive control demonstrated a significant inhibition of myostatin gene expression (57% of untreated control cells, p<0.001,Fig. 1B).”
Quote in the paperNot a substantial claim - Findingown data
20E binding tests for AR, ERα, and ERβ were all negative at up to 100 μM.
“We too performed binding tests of 20E for AR, ERα and ERβ which were all negative at up to 100 µM (data not shown).”
Quote in the paperSubstantial claim - Findingown data
Downregulation of Mas receptor by SiRNA MAS significantly decreases MAS gene expression by a factor 2 in all transfected groups versus scramble SiRNA.
“A significant decrease of MAS gene expression by a factor 2 in all transfected group by directed SiRNA versus scramble SiRNA was observed (Supporting Fig. S5).”
Quote in the paperSubstantial claim - Findingown data
20E inhibitory effect on myostatin gene expression is fully reverted by Ang 1-7 antagonists A1 or A779 (10 μM).
“Interestingly, 20E inhibitory effects on myostatin gene expression was also fully reverted by the same antagonists (Fig. 3A)”
Quote in the paperSubstantial claim- Rests on an assumption: The Ang 1-7 antagonists A1 and A779 are specific for the Mas receptor.
- Findingown data
Downregulation of Mas receptor reverses 20E or Ang1-7 effects on myostatin gene expression.
“down regulation of Mas receptor reversed 20E or Ang1-7 effects on myostatin gene expression (Fig. 3B).”
Quote in the paperSubstantial claim - Findingown data
GPR30 agonists and antagonists exclude GPR30 from candidates for the E2 receptor involved in effects on muscle cells.
“Our experiments with GPR30 agonists and antagonists exclude GPR30 from the candidates.”
Quote in the paperSubstantial claim - Findingown data
The effect of IGF-1 on myostatin gene expression remains unchanged in the presence or absence of Ang 1-7 antagonist.
“In contrast, the effect of IGF-1, which acts through its own receptor (insulin-like growth factor 1 receptor; IGF1R) remains unchanged in the presence or in the 6 absence of Ang 1-7 antagonist (Supporting Fig. S4).”
Quote in the paperSubstantial claim - Findingown data
E2 significantly inhibits myostatin gene expression in C2C12 myotubes from 0.1 μM to 1 μM.
“E2 significantly inhibits myostatin gene expression from 0. 1 µM to 1 µM (Fig. 4A).”
Quote in the paperSubstantial claim - Findingown data
E2 effect on myostatin gene expression is not inhibited by Mas antagonist A779.
“E2 effect on myostatin was tested in the presence of a Mas antagonist (A779) but, unexpectedly, the effect of E2 was not inhibited by A779 (Fig. 4C).”
Quote in the paperNot a substantial claim - Findingown data
Angiotensin-(1-7) (10 μM) inhibition of myostatin gene expression is totally abolished by specific Ang 1-7 antagonists A1 or A779 (10 μM).
“As expected, this inhibition by Ang 1-7 (10 µM) was totally abolished by specific Ang 1-7 antagonists (A1 or A779, 10 µM) (Fig. 3A).”
Quote in the paperSubstantial claim- Rests on an assumption: The Ang 1-7 antagonists A1 and A779 are specific for the Mas receptor.
- Findingown data
Among selected GPCRs, only Mas receptor gave positive data with 20E using in silico binding, in vitro binding, agonist comparison, or antagonist effects.
“Using this approach, the only receptor which gave positive data was Mas, the receptor of angiotensin-(1-7).”
Quote in the paperSubstantial claim - Findingown data
Downregulation of Mas receptor has no impact on the effect of IGF-1 on myostatin gene expression.
“As expected, and consistently with the pharmacological approach, down regulation of Mas receptor had no impact on the effect of IGF-1 on myostatin gene expression (data not shown).”
Quote in the paperNot a substantial claim - Findingown data
Angiotensin-(1-7) partially inhibits myostatin gene expression in C2C12 cells in a dose-dependent manner.
“Angiotensin-(1-7) (Ang 1-7, Supporting Fig. S3) as well as 20E (Fig. 1B) partially inhibits myostatin gene expression in a dose-dependent manner.”
Quote in the paperSubstantial claim - Findingown data
The membrane-impermeable 20E derivative 22S-HSA conjugate retains activity similar to free 20E on myostatin gene expression at 10 μM 20E-equivalents.
“We observed that the membrane-impermeable 20Ederivative retained an activity similar to that of free 20E.”
Quote in the paperSubstantial claim- Rests on an assumption: The 20E-HSA conjugate is membrane-impermeable.
- Findingown data
17α-E2 is active for inhibition of MSTN gene activity.
“This compound proved active for the inhibition of MSTN gene activity (Supporting Fig. S6).”
Quote in the paperSubstantial claim - Findingown data
An off-target safety screen for 87 receptors was negative for ERα and AR.
“Similarly, an off-target safety screen for 87 receptors was equally negative for ERα and AR (Supporting Table S1).”
Quote in the paperNot a substantial claim - Findingown data
Mas antagonists A1 and A779 block the inhibitory effects of 20E and Ang1-7 on myostatin gene expression.
“Mas antagonists (A1 and A779) blocked 20E and Ang 1-7 inhibitory activities on myostatin gene expression determined by qRT-PCR.”
Quote in the paperSubstantial claim - Findingown data
Angiotensin-(1-7) inhibits myostatin gene expression in C2C12 myotubes.
“Mas antagonists (A1 and A779) blocked 20E and Ang 1-7 inhibitory activities on myostatin gene expression determined by qRT-PCR.”
Quote in the paperSubstantial claim - Findingown data
MAS siRNA abolishes 20E- and Ang1-7-induced inhibition of myostatin gene expression.
“MAS siRNA abolished 20E-and Ang 1-7-induced myostatin inhibition.”
Quote in the paperSubstantial claim - Findingown data
20E inhibits myostatin gene expression in C2C12 myotubes.
“Mas antagonists (A1 and A779) blocked 20E and Ang 1-7 inhibitory activities on myostatin gene expression determined by qRT-PCR.”
Quote in the paperSubstantial claim - Findingown data
17β-Estradiol-mediated myostatin inhibition is not blunted by Mas antagonist A779.
“17β-Estradiol-mediated myostatin inhibition is not linked with a transmembrane receptor and is not blunted by a Mas antagonist.”
Quote in the paperSubstantial claim - Findingown data
20E affects protein synthesis in differentiated C2C12 myotubes.
“Experiments displaying 20E effects on protein synthesis in differentiated myotubes detected by [3H]-leucin incorporation.”
Quote in the paperNot a substantial claim - Findingown data
20E at 10 μM does not significantly inhibit specific ligand binding to any of the 45 selected GPCRs and 5 nuclear receptors tested.
“None of these inhibitions were considered significant.”
Quote in the paperNot a substantial claim - Interpretationreasoning
A complex associating Mas and an estrogen membrane receptor (likely with caveolin and/or striatin and additional transduction effectors) best fits the data.
“Taken together, our data best fit with the presence of a complex associating Mas and a estrogen membrane receptor (Fig. 5), likely together with a caveolin and/or striatin, as well as additional transduction effectors (e.g.Gq, NOS, …).”
Quote in the paperSubstantial claim - Interpretationreasoning
A mechanism involving cooperation between Mas receptor and a membrane-bound palmitoylated estrogen receptor is proposed.
“A mechanism involving cooperation between Mas receptor and a membrane-bound palmitoylated estrogen receptor is proposed.”
Quote in the paperSubstantial claim - Interpretationreasoning§ 20-Hydroxyecdysone activates the protective arm of the renin angiotensin system via Mas receptor
20E activates the protective arm of the renin angiotensin system via Mas receptor.
“20-Hydroxyecdysone activates the protective arm of the renin angiotensin system via Mas receptor”
Quote in the paperNot a substantial claim - Interpretationown data
Inhibition of myostatin gene expression by 20E (or Ang 1-7) is mediated by the receptor of Ang 1-7 (Mas).
“suggesting that inhibition of myostatin gene expression by 20E (or Ang 1-7) is mediated by the receptor of Ang 1-7.”
Quote in the paperSubstantial claim- Rests on an assumption: The Ang 1-7 antagonists A1 and A779 are specific for the Mas receptor.
- Premisecitation
20E bound to metallic nanoparticles, preventing its entrance in target cells, is still active.
“20E bound to metallic nanoparticles, preventing its entrance in target cells, is still active (27).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [27] 2001, Signal transduction of erythrocytes after specific binding of ecdysterone and cholesterol immobilized on nanodispersed magnetite, J Magn Magn Mater source
Not checked in the free run.
- Premisecitation
There is no direct evidence for the binding of 20E to nuclear estrogen (or androgen) receptors.
“There is in fact no direct evidence for the binding of 20E to nuclear estrogen (or androgen) receptors (12,13).”
Quote in the paperNot a substantial claim0 of 2 sources checked - Study design and conductown data
MAS-inhibiting siRNA inhibits MAS expression in C2C12 cells.
“Inhibition of MAS expression by specific SiRNA.”
Quote in the paperSubstantial claim - Premisereasoning
The above pharmacological arguments appear strong enough to consider that the cell membrane is (maybe not exclusively) a site of action of 20E.
“The above pharmacological arguments appear strong enough to consider that the cell membrane is (maybe not exclusively) a site of action of 20E.”
Quote in the paperNot a substantial claim - Interpretationown data
20E acts on C2C12 myotubes from outside the cell.
“20E acts on C2C12 myotubes from outside of the cell.”
Quote in the paperSubstantial claim - Interpretationnone given
The effects of Angiotensin (1-7), AVE 0991, 20E and estradiol are closely similar.
“The close similarity of Angiotensin (1-7), AVE 0991, 20E and estradiol effects.”
Quote in the paperSubstantial claim - Interpretationown data
20-Hydroxyecdysone effects are mediated through Mas receptor activation.
“20-Hydroxyecdysone effects are mediated through Mas receptor activation.”
Quote in the paperSubstantial claim
- Classified as probably not a substantial claim. 8
- May combine two claims. 9
Probably not a substantial claim: may not pass S3 (load-bearing).
FindingcitationIGF-1 (100 ng/mL) improves [3H]-Leu incorporation by +20% (p<0.001) in C2C12 myotubes.
“IGF-1 (100 ng/mL), employed as positive control (30) displayed, as expected, an improvement in [ 3 H]-Leu incorporation (+20%, p < 0.001).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [30] source
Not checked in the free run.
May combine two claims.
Findingown dataE2-CMO-BSA conjugate is inactive and does not significantly decrease myostatin expression (-8%, ns).
“By contrast, E2-CMO-BSA-conjugate was inactive (Fig. 4B) and did not significantly decrease myostatin expression (-8 %, ns).”
Quote in the paperSubstantial claim- Rests on an assumption: The E2-CMO-BSA conjugate is membrane-impermeable.
May combine two claims.
Findingown dataE2-CMO significantly inhibits myostatin gene expression (-39%, p<0.05) with the same trend as IGF-1 positive control (-47%, p<0.01).
“E2-CMO significantly inhibited myostatin gene expression (-39%, p < 0.05) with the same trend as IGF-1 positive control (-47%, p < 0.01).”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Findingown data17α-estradiol inhibits myostatin gene expression in differentiated C2C12 cells.
“Inhibitory activity of 17α-estradiol (αE2) on myostatin gene expression.”
Quote in the paperNot a substantial claimMay combine two claims.
InterpretationreasoningThe effects of 20E on C2C12 cells involve both Mas receptor and a non-nuclear estradiol receptor.
“Our data combined with those previously available from the literature allow us to conclude that the effects of 20E on C2C12 cells involve both Mas receptor and a nonnuclear estradiol receptor.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductreasoningC2C12 cells were maintained at low passage (3-20 passages) for all experiments to maintain the differentiation potential of the cultures.
“C2C12 cells were maintained at low passage (3-20 passages) for all experiments to maintain the differentiation potential of the cultures.”
Quote in the paperNot a substantial claimMay combine two claims.
Interpretationown data20E does not bind the concerned ER receptor, and activation of this estrogen receptor by 20E is secondary to Mas activation.
“This allows us to conclude that 20E does not bind the concerned ER receptor, and that the activation of this estrogen receptor by 20E is secondary to Mas activation.”
Quote in the paperSubstantial claim- Rests on an assumption: The 20E-HSA conjugate is membrane-impermeable.
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationThe clinical evidence for 20E effectiveness in humans remains limited at the moment.
“While many effects have been described on animals (10,12,13), the clinical evidence for 20E effectiveness in humans remains limited at the moment (14)(15)(16).”
Quote in the paperNot a substantial claim0 of 3 sources checked- cites [14] 2019, Ecdysteroids as non-conventional anabolic agent: performance enhancement by ecdysterone supplementation in humans, Arch Toxicol source
Not checked in the free run.
- cites [15] 1988, Combined application of preparation Ecdysten and product Bodrost during training in cyclic sports, Scientific Sports Bulletin
Not checked in the free run.
- cites [16] 2015, Eine neue Alternative für die Prävention und Therapie postmenopausaler Erkrankungen, insbesondere des metabolischen Syndroms, J. Gynäkol. Endokrinol
Not checked in the free run.
May combine two claims.
Interpretationown dataThe presence of a bulky protein does not prevent 20E activity, which is an additional argument for interaction of 20E with a membrane receptor.
“This results demonstrates that the presence of a bulky protein does not prevent 20E activity and is an additional argument for the interaction of 20E with a membrane receptor, as proposed by Gorelick-Feldman et al. (2010).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites Gorelick-Feldman et al. (2010)
Not checked in the free run.
- Rests on an assumption: The 20E-HSA conjugate is membrane-impermeable.
Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
Interpretationcitation20E is devoid of any feminizing activity and is probably inactive on estrogen-dependent cancer cells.
“Thus 20E is devoid of any feminizing activity (13,56) and is probably inactive on estrogen-dependent cancer cells.”
Quote in the paperNot a substantial claim0 of 2 sources checkedClassified as probably not a substantial claim.
Study design and conductcitationThe myostatin transcript bioassay was developed and standardized in order to assess ecdysteroid activity.
“The myostatin transcript bioassay was developed and standardized in order to assess ecdysteroid activity (31).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [31] 2012, <i>In Vitro</i> Characterization of the Efficacy and Safety Profile of a Proprietary Ajuga Turkestanica Extract, Chinese Medicine source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
PremisecitationSeveral data favour an action on membranes through a GPCR receptor, whereas other ones suggest the involvement of a nuclear receptor, the estrogen receptor ERβ.
“Several data favour an action on membranes through a GPCR receptor (17), whereas other ones suggest the involvement of a nuclear receptor, the estrogen receptor ERβ (18,19).”
Quote in the paperNot a substantial claim0 of 3 sources checked- cites [17] source
Not checked in the free run.
- cites [18] 2018, Pharmacology of doping agents – mechanisms promoting muscle hypertrophy, AIMS Molecular Science
Not checked in the free run.
- cites [19] 2014, Estrogen receptor beta is involved in skeletal muscle hypertrophy induced by the phytoecdysteroid ecdysterone, Mol Nutr Food Res source
Not checked in the free run.
May combine two claims.
Interpretationown data17β-Estradiol-mediated myostatin inhibition is not linked with a transmembrane receptor.
“17β-Estradiol-mediated myostatin inhibition is not linked with a transmembrane receptor and is not blunted by a Mas antagonist.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
PremisecitationGorelick-Feldman et al. concluded that the membrane 20E receptor belongs to the GPCR family and proposed a mechanism of transduction involving an unidentified GPCR and a membrane calcium channel.
“They concluded that the membrane 20E receptor belongs to the GPCR family and proposed a mechanism of transduction involving an unidentified GPCR and a membrane calcium channel (Supporting Fig. S1).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [17] source
Not checked in the free run.
The paper relies on this without support.
Myostatin is a major autocrine regulator that inhibits muscle growth in mammals.
“Myostatin is a major autocrine regulator that inhibits muscle growth in mammals.”
The paper relies on this without support.
The C2C12 mouse myoblast cell line is a valid model for studying muscle anabolism and 20E effects on muscle.
“The C2C12 mouse myoblast cell line (29) was purchased from ATCC (CRL-1772).”
The paper relies on this without support.
The Ang 1-7 antagonists A1 and A779 are specific for the Mas receptor.
“As expected, this inhibition by Ang 1-7 (10 µM) was totally abolished by specific Ang 1-7 antagonists (A1 or A779, 10 µM) (Fig. 3A).”
The paper relies on this without support.
The E2-CMO-BSA conjugate is membrane-impermeable.
“We used a membrane-impermeable conjugate of E2 made of bovine serum albumin (BSA) and a carboxymethyloxime (CMO) linker.”
The paper relies on this without support.
The 20E-HSA conjugate is membrane-impermeable.
“a membraneimpermeable derivative of 20E was produced (Supporting Fig. S2).”
The paper relies on this without support.
The mechanism of action of ecdysteroids on mammals/humans has not been elucidated.
“In spite of more than 40 years of research, the mechanism of action of these molecules on mammals/humans has not been elucidated, as only diverging reports are available for the moment.”
The paper relies on this without support.
20E is safe for therapeutic use.
“The possibility to activate the Mas receptor with a safe steroid molecule is consistent with the pleiotropic pharmacological effects of ecdysteroids in mammals”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The mechanism of action of 20E is not yet fully understood.
“The mechanism of action of 20E is not yet fully understood [170,192].”
From Ecdysteroids (2021) · cites this paper as [192]
Low 20E concentration enhanced the growth of insect cells and protein synthesis in mice myotubes, whereas high concentration inhibited these processes.
“For instance, it was reported that low 20E concentration enhanced the growth of insect cells [88] and protein synthesis in mice myotubes [89], whereas a high concentration inhibited these processes.”
From 20-Hydroxyecdysone Confers Antioxidant and Antineoplastic Properties in Human Non-Small Cell Lung Cancer Cells (2023) · cites this paper as [89]
The same phenomenon (lesser effects at high concentration) has been reported by other authors in different biological systems.
“The same phenomenon has been reported by other authors in different biological systems [88,89].”
From 20-Hydroxyecdysone Confers Antioxidant and Antineoplastic Properties in Human Non-Small Cell Lung Cancer Cells (2023) · cites this paper as [89]
Cites
Serial passaging and differentiation of myogenic cells isolated from dystrophic mouse muscle
Yaffe, D., & Saxel, O. (1977) · Nature · doi:10.1038/270725a0 · Cited by 2,153 · see citing works
TGR5-Mediated Bile Acid Sensing Controls Glucose Homeostasis
Thomas, C., Gioiello, A., Noriega, L., Strehle, A., Oury, J., Rizzo, G., Macchiarulo, A., Yamamoto, H., Mataki, C., Pruzanski, M., et al. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2009.08.001 · Cited by 1,885 · see citing works
Bile Acid Metabolism and Signaling
Chiang, J. Y. L. (2013) · Comprehensive physiology · doi:10.1002/cphy.c120023 · Cited by 1,390 · see citing works
Filardo, E. J., Quinn, J. A., Bland, K. I., & Frackelton, A. R. (2000) · Molecular Endocrinology · doi:10.1210/mend.14.10.0532 · Cited by 1,387 · see citing works
Estrogen Signaling through the Transmembrane G Protein–Coupled Receptor GPR30
Prossnitz, E. R., Arterburn, J. B., Smith, H. O., Oprea, T. I., Sklar, L. A., & Hathaway, H. J. (2008) · Annual Review of Physiology · doi:10.1146/annurev.physiol.70.113006.100518 · Cited by 590 · see citing works
Estrogen deficiency and the origin of obesity during menopause
Lizcano, F., & Guzmán, G. (2014) · BioMed Research International · doi:10.1155/2014/757461 · Cited by 586 · see citing works
ACE2 , angiotensin‐(1‐7) and M as receptor axis in inflammation and fibrosis
Silva, A. C. S. E., da Silveira, K. D., Ferreira, A., & Teixeira, M. M. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12159 · Cited by 546 · see citing works
The neuroprotective actions of oestradiol and oestrogen receptors
Arévalo, M., Azcoitia, Í., & García‐Segura, L. M. (2014) · Nature reviews. Neuroscience · doi:10.1038/nrn3856 · Cited by 478 · see citing works
Discovery and Characterization of Alamandine
Lautner, R. Q., Villela, D. C., Fraga-Silva, R. A., Silva, N., Verano‐Braga, T., Costa-Fraga, F. P., Jankowski, J., Jankowski, V., Sousa, F. B. D., Alzamora, A. C., et al. (2013) · Circulation Research · doi:10.1161/circresaha.113.301077 · Cited by 440 · see citing works
Oestrogen increases haematopoietic stem-cell self-renewal in females and during pregnancy
Nakada, D., Oguro, H., Levi, B. P., Ryan, N., Kitano, A., Saitoh, Y., Takeichi, M., Wendt, G. R., & Morrison, S. J. (2014) · Nature · doi:10.1038/nature12932 · Cited by 409 · see citing works
Effect of Estrogen on Musculoskeletal Performance and Injury Risk
Chidi-Ogbolu, N., & Baar, K. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2018.01834 · Cited by 389 · see citing works
The discovery of angiotensin‐converting enzyme 2 and its role in acute lung injury in mice
Imai, Y., Kuba, K., & Penninger, J. M. (2008) · Experimental Physiology · doi:10.1113/expphysiol.2007.040048 · Cited by 335 · see citing works
Mauvais-Jarvis, F. (2011) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2010.10.002 · Cited by 335 · see citing works
Angiotensin-(1–7) inhibits growth of cardiac myocytes through activation of themasreceptor
Tallant, E. A., Ferrario, C. M., & Gallagher, P. E. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00941.2004 · Cited by 317 · see citing works
Rapid Estrogen Signaling in the Brain
Raz, L., Khan, M. M., Mahesh, V. B., Vadlamudi, R. K., & Brann, D. W. (2008) · Neurosignals · doi:10.1159/000111559 · Cited by 201 · see citing works
Phytoecdysteroids and Anabolic Androgenic Steroids--Structure and Effects on Humans
Bathori, M., Toth, N., Hunyadi, A., Marki, A., & Zador, E. (2008) · Current Medicinal Chemistry · doi:10.2174/092986708783330674 · Cited by 201 · see citing works
Effects and applications of arthropod steroid hormones (ecdysteroids) in mammals
Dinan, L., & Lafont, R. (2006) · Journal of Endocrinology · doi:10.1677/joe.1.06900 · Cited by 200 · see citing works
Self-citationModulation of G Protein-Coupled Receptors by an Estrogen Receptor that Activates Protein Kinase A
Lagrange, A. H., Rønnekleiv, O. K., & Kelly, M. J. (1997) · Molecular Pharmacology · doi:10.1124/mol.51.4.605 · Cited by 197 · see citing works
Pelekanou, V., Kampa, M., Kiagiadaki, F., Deli, A., Theodoropoulos, P., Agrogiannis, G., Patsouris, E., Tsapis, A., Castanas, E., & Notas, G. (2016) · Journal of Leukocyte Biology · doi:10.1189/jlb.3a0914-430rr · Cited by 184 · see citing works
Nonpeptide AVE 0991 Is an Angiotensin-(1–7) Receptor Mas Agonist in the Mouse Kidney
Pinheiro, S. V. B., Silva, A. C. S. E., Sampaio, W. O., de Paula, R. D., Mendes, E. P., Bontempo, E. D., Pesquero, J. B., Walther, T., Alenina, N. V., Bäder, M., et al. (2004) · Hypertension · doi:10.1161/01.hyp.0000141438.64887.42 · Cited by 175 · see citing works
Mo, J., Enkhjargal, B., Travis, Z. D., Zhou, K., Wu, P., Zhang, G., Zhu, Q., Zhang, T., Peng, J., Xu, W., et al. (2018) · Redox Biology · doi:10.1016/j.redox.2018.09.022 · Cited by 174 · see citing works
Angiotensin-(1–7) prevents diabetes-induced cardiovascular dysfunction
Benter, I. F., Yousif, M. H. M., Cojocel, C., Al‐Maghrebi, M., & Diz, D. I. (2007) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00372.2006 · Cited by 167 · see citing works
Phytoecdysteroids increase protein synthesis in skeletal muscle cells.
Gorelick-Feldman, J., MacLean, D., Ilic, N., Poulev, A., Lila, M. A., Cheng, D., & Raskin, I. (2008) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf073059z · Cited by 166 · see citing works
Estrogen and the Brain: Beyond ER‐α, ER‐β, and 17β‐Estradiol
Toran‐Allerand, C. D. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1347.009 · Cited by 164 · see citing works
Renin‐Angiotensin System: An Old Player with Novel Functions in Skeletal Muscle
Cabello‐Verrugio, C., Morales, M. G., Rivera, J. C. A., Cabrera, D., & Simón, F. (2015) · Medicinal Research Reviews · doi:10.1002/med.21343 · Cited by 164 · see citing works
Selective estrogen receptor-β activation stimulates skeletal muscle growth and regeneration
Velders, M., Schleipen, B., Fritzemeier, K. H., Zierau, O., & Diel, P. (2012) · The FASEB Journal · doi:10.1096/fj.11-194779 · Cited by 162 · see citing works
ACE2 and Ang-(1-7) Confer Protection Against Development of Diabetic Retinopathy
Verma, A., Shan, Z. J., Lei, B., Yuan, L., Liu, X., Nakagawa, T., Grant, M. B., Lewin, A. S., Hauswirth, W. W., Raizada, M. K., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.155 · Cited by 159 · see citing works
Acuña, M. J., Pessina, P., Olguín, H. C., Cabrera, D., Vio, C. P., Bäder, M., Muñoz‐Cánoves, P., Santos, R. A. S., Cabello‐Verrugio, C., & Brandan, E. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt514 · Cited by 159 · see citing works
El‐Hashim, A. Z., Renno, W. M., Raghupathy, R., Abduo, H., Akhtar, S., & Benter, I. F. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.01905.x · Cited by 154 · see citing works
Vasoprotective and Atheroprotective Effects of Angiotensin (1-7) in Apolipoprotein E–Deficient Mice
Tesanovic, S., Vinh, A., Gaspari, T. A., CASLEY, D. J., & Widdop, R. E. (2010) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.110.204453 · Cited by 151 · see citing works
Lebesgue, D., Traub, M., Butte-Smith, M. D., Chen, C. H., Zukin, R. S., Kelly, M. J., & Etgen, A. M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008642 · Cited by 146 · see citing works
Lemos, V. S., Silva, D. M. R., Walther, T., Alenina, N. V., Bäder, M., & Santos, R. A. S. (2005) · Journal of Cardiovascular Pharmacology · doi:10.1097/01.fjc.0000175237.41573.63 · Cited by 128 · see citing works
Anti-inflammatory effects of angiotensin-(1-7) in ischemic stroke
Regenhardt, R. W., Desland, F., Mecca, A., Pioquinto, D. J., Afzal, A., Mocco, J., & Sumners, C. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.03.025 · Cited by 128 · see citing works
Isenmann, E., Ambrosio, G., Joseph, J. F., Mazzarino, M., de la Torre, X., Zimmer, P., Kazlauskas, R., Goebel, C., Botrè, F., Diel, P., et al. (2019) · Archives of Toxicology · doi:10.1007/s00204-019-02490-x · Cited by 127 · see citing works
Ferreira, A. J., Jacoby, B. A., Araújo, C. A. A., Macedo, F. A. F. F., Silva, G. A. B., Almeida, A. P., Caliari, M. V., & Santos, R. A. S. (2006) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00828.2006 · Cited by 127 · see citing works
Skiba, D. S., Nosalski, R., Mikolajczyk, T. P., Siedliński, M., Rios, F. J. O., Montezano, A. C. I., Jawień, J., Olszanecki, R., Korbut, R., Cześnikiewicz‐Guzik, M., et al. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13685 · Cited by 125 · see citing works
Foucault, A., Mathé, V., Lafont, R., Even, P., Dioh, W., Veillet, S., Tomé, D., Huneau, J., Hermier, D., & Quignard‐Boulangé, A. (2012) · Obesity · doi:10.1038/oby.2011.257 · Cited by 122 · see citing works
Self-citation20-Hydroxyecdysone decreases weight and hyperglycemia in a diet-induced obesity mice model
Kizelsztein, P., Govorko, D., Komarnytsky, S., Evans, A., Wang, Z., Cefalu, W. T., & Raskin, I. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90772.2008 · Cited by 117 · see citing works
Angiotensin-(1–7) Protects From Experimental Acute Lung Injury
Klein, N., Gembardt, F., Supé, S., Kaestle, S. M., Nickles, H. T., Erfinanda, L., Lei, X., Yin, J., Wang, L., Mertens, M., et al. (2013) · Critical Care Medicine · doi:10.1097/ccm.0b013e31828a6688 · Cited by 115 · see citing works
Pereira, R. M., Santos, R. A. S., Teixeira, M. M., Leite, V. H. R., Costa, L. P., Dias, F. L. D. C., Barcelos, L. S., Collares, G. B., & Silva, A. C. S. E. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2006.10.018 · Cited by 109 · see citing works
Parr, M. K., Zhao, P., Haupt, O., Ngueu, S. T., Hengevoss, J., Fritzemeier, K. H., Piechotta, M., Schlörer, N., Muhn, P., Zheng, W., et al. (2014) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201300806 · Cited by 106 · cited 4× · see citing works
“The evidence of ERβ involvement in 20E effect is based on the use of specific pharmacological activators or inhibitors of ERs, the former being able to mimic and the latter to inhibit the effects of 20E on target cells such as osteoblasts (20) or myoblasts (19).”
BackgroundInfluentialThe Karlson Lecture. Phytoecdysteroids: what use are they?
Dinan, L. (2009) · Archives of Insect Biochemistry and Physiology · doi:10.1002/arch.20334 · Cited by 106 · cited 1× · see citing works
“Ecdysteroids are a large family of steroids initially discovered in arthropods (zooecdysteroids) and later in plants (phytoecdysteroids) (9).”
BackgroundSEMSARIAN, C., SUTRAVE, P., RICHMOND, D. R., & GRAHAM, R. M. (1999) · Biochemical Journal · doi:10.1042/bj3390443 · Cited by 106 · see citing works
30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Nongenomic effects via the mineralocorticoid receptor
Ruhs, S., Nolze, A., Hübschmann, R., & Großmann, C. (2017) · Journal of Endocrinology · doi:10.1530/joe-16-0659 · Cited by 105 · see citing works
Gorelick-Feldman, J., Cohick, W., & Raskin, I. (2010) · Steroids · doi:10.1016/j.steroids.2010.03.008 · Cited by 96 · cited 6× · see citing works
“This results demonstrates that the presence of a bulky protein does not prevent 20E activity and is an additional argument for the interaction of 20E with a membrane receptor, as proposed by Gorelick-Feldman et al. (2010).”
BackgroundMethodInfluentialEcdysteroids: A novel class of anabolic agents?
Parr, M., Botrè, F., Naß, A., Hengevoss, J., Diel, P., & Wolber, G. (2014) · Biology of Sport · doi:10.5604/20831862.1144420 · Cited by 95 · cited 2× · see citing works
“(19,22) have proposed that 20E effects are explained through its binding to estrogen receptor ERβ.”
BackgroundResultLubel, J. S., Herath, C. B., Tchongue, J., Grace, J., Jia, Z., Spencer, K., CASLEY, D. J., Crowley, P. F., Sievert, W., Burrell, L. M., et al. (2009) · Clinical Science · doi:10.1042/cs20080647 · Cited by 95 · see citing works
Liu, C., Lv, X.-H., Li, H., Cao, X., Zhang, F., Wang, L., Mei, Y., & Yang, J. (2011) · Acta Diabetologica · doi:10.1007/s00592-011-0348-z · Cited by 95 · see citing works
Palmitoylation of Estrogen Receptors Is Essential for Neuronal Membrane Signaling
Meitzen, J., Luoma, J. I., Boulware, M. I., Hedges, V. L., Peterson, B. M., Tuomela, K. E., Britson, K. A., & Mermelstein, P. G. (2013) · Endocrinology · doi:10.1210/en.2013-1172 · Cited by 94 · see citing works
Santos, S. H. S., Fernandes, L. R., Pereira, C. S., Guimarães, A. L. S., de Paula, A. M. B., Campagnole‐Santos, M. J., Alvarez-Leite, J. I., Bäder, M., & Santos, R. A. S. (2012) · Regulatory Peptides · doi:10.1016/j.regpep.2012.06.009 · Cited by 91 · see citing works
DYKENS, J. A., MOOS, W. H., & HOWELL, N. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1347.008 · Cited by 87 · see citing works
Oral administration of angiotensin-(1–7) ameliorates type 2 diabetes in rats
Santos, S. H. S., Giani, J. F., Burghi, V., Miquet, J. G., Qadri, F., Braga, J. F., Todiraş, M., Kotnik, K., Alenina, N. V., Dominici, F. P., et al. (2013) · Journal of Molecular Medicine · doi:10.1007/s00109-013-1087-0 · Cited by 86 · see citing works
20-Hydroxyecdysone Increases Fiber Size in a Muscle-Specific Fashion in Rat
Tóth, N., Szabó, A., Kacsala, P., Héger, J., & Zádor, E. (2008) · Phytomedicine · doi:10.1016/j.phymed.2008.04.015 · Cited by 85 · see citing works
Zheng, J., Li, G., Chen, S., Bihl, J. C., Buck, J., Zhu, Y., Xia, H., Lazartigues, E. D., Chen, Y., & Olson, J. E. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.04.060 · Cited by 84 · see citing works
Cisternas, F., Morales, M. G., Meneses, C., Simon, F., Brandan, E., Abrigo, J., Vazquez, Y., & Cabello-Verrugio, C. (2015) · Clinical Science · doi:10.1042/cs20140215 · Cited by 83 · see citing works
Jiang, T., Gao, L., Shi, J., Lu, J., Wang, Y., & Zhang, Y. (2012) · Pharmacological Research · doi:10.1016/j.phrs.2012.10.014 · Cited by 83 · see citing works
Andrade, J. M. O., Paraíso, A. F., Garcia, Z. M., Ferreira, A. V. M., Sinisterra, R. D., Sousa, F. B. D., Guimarães, A. L. S., de Paula, A. M. B., Campagnole‐Santos, M. J., Santos, R. A. S., et al. (2014) · Peptides · doi:10.1016/j.peptides.2014.03.006 · Cited by 83 · see citing works
Angiotensin‐(1‐7) attenuates metastatic prostate cancer and reduces osteoclastogenesis
Krishnan, B., Smith, T. L., Dubey, P., Zapadka, M. E., Torti, F. M., Willingham, M. C., Tallant, E. A., & Gallagher, P. E. (2012) · The Prostate · doi:10.1002/pros.22542 · Cited by 83 · see citing works
Rodrigues‐Machado, M. D. G., Magalhães, G. S., Cardoso, J. A., Kangussu, L. M., Murari, A., Caliari, M. V., Oliveira, M. L., Cara, D. C., Noviello, M. L. M., Marques, F. D., et al. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12318 · Cited by 81 · see citing works
Membrane Receptors for Vitamin D Metabolites
Khanal, R. C., & Nemere, I. (2007) · Critical Reviews in Eukaryotic Gene Expression · doi:10.1615/critreveukargeneexpr.v17.i1.30 · Cited by 79 · see citing works
Oestradiol is a protective factor for non‐alcoholic fatty liver disease in healthy men
Tian, G., Sun, Y., Pang, C., Tan, A., Gao, Y., Zhang, H., Yang, X., Li, Z., & Mo, Z. (2012) · Obesity Reviews · doi:10.1111/j.1467-789x.2011.00978.x · Cited by 78 · see citing works
Angiotensin-(1-7) attenuates disuse skeletal muscle atrophy via the Mas receptor
Morales, M. G., Abrigo, J., Acuña, M. J., Santos, R. A., Bader, M., Brandan, E., Simon, F., Olguin, H., Cabrera, D., & Cabello-Verrugio, C. (2016) · Disease Models & Mechanisms · doi:10.1242/dmm.023390 · Cited by 77 · see citing works
Effect of Ecdysterone on Hyperglycemia in Experimental Animals
Yoshida, T., Otaka, T., Uchiyama, M., & Ogawa, S. (1971) · Biochemical Pharmacology · doi:10.1016/0006-2952(71)90431-x · Cited by 74 · see citing works
(2013) · European Journal of Entomology · Cited by 72 · see citing works
Self-citationda Silveira, K. D., Barroso, L. C., Vieira, A. T., Cisalpino, D., Lima, C. X., Bäder, M., Arantes, R. M. E., Santos, R. A. S., Silva, A. C. S. E., & Teixeira, M. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066082 · Cited by 72 · see citing works
Presence of Functional Oxytocin Receptors in Cultured Human Myoblasts
Breton, C., Haenggeli, C., Barberis, C., Heitz, F., Bader, C. R., Bernheim, L., & Tribollet, E. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8537 · Cited by 71 · see citing works
Muñoz, M. C., Giani, J. F., & Dominici, F. P. (2010) · Regulatory Peptides · doi:10.1016/j.regpep.2010.02.001 · Cited by 69 · see citing works
Raffai, G., Durand, M. J., & Lombard, J. H. (2011) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00202.2011 · Cited by 68 · see citing works
Angiotensin 1–7 improves insulin sensitivity by increasing skeletal muscle glucose uptake in vivo
Echeverría‐Rodríguez, O., del Valle‐Mondragón, L., & Hong, E. (2013) · Peptides · doi:10.1016/j.peptides.2013.10.022 · Cited by 67 · see citing works
Hu, J., Luo, C. X., Chu, W. H., Shan, Y. A., Qian, Z.-M., Zhu, G., Yu, Y. B., & Feng, H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050764 · Cited by 67 · see citing works
Kapur, P., Wuttke, W., Jarry, H., & Seidlova-Wuttke, D. (2010) · Phytomedicine · doi:10.1016/j.phymed.2010.01.005 · Cited by 66 · see citing works
Barroso, L. C., da Silveira, K. D., Lima, C. X., Borges, V. O., Bäder, M., Rachid, M. A., Santos, R. A. S., Souza, D. G., Silva, A. C. S. E., & Teixeira, M. M. (2012) · International Journal of Hypertension · doi:10.1155/2012/808726 · Cited by 65 · see citing works
Membrane-initiated estradiol actions mediate structural plasticity and reproduction
Micevych, P. E., & Christensen, A. (2012) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2012.07.003 · Cited by 62 · see citing works
Bertrand, C., Pignalosa, A., Wanecq, E., Rancoule, C., Batut, A., Deleruyelle, S., Lionetti, L., Valet, P., & Castan‐Laurell, I. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078874 · Cited by 61 · see citing works
Gao, L., Cai, G., & Shi, X. (2008) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.31.2245 · Cited by 61 · see citing works
The angiotensin-(1–7) receptor agonist AVE0991 is cardioprotective in diabetic rats
Ebermann, L., Spillmann, F., Sidiropoulos, M., Escher, F., Heringer‐Walther, S., Schultheiß, H., Tschöpe, C., & Walther, T. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.05.024 · Cited by 61 · see citing works
Angiotensin 1–7: A peptide for preventing and treating metabolic syndrome
Santos, S. H. S., & Andrade, J. M. O. (2014) · Peptides · doi:10.1016/j.peptides.2014.07.002 · Cited by 58 · see citing works
Metabolic Effects of 20-OH-Ecdysone in Ovariectomized Rats
Seidlova-Wuttke, D., Ehrhardt, C., & Wuttke, W. (2010) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2010.01.006 · Cited by 57 · see citing works
Schuchard, J., Winkler, M., Stölting, I., Schuster, F., VOGT, F. M., Barkhausen, J., Thorns, C., Santos, R. A. S., Bäder, M., & Raasch, W. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13172 · Cited by 57 · see citing works
Breithaupt‐Faloppa, A. C., Fantozzi, E. T., Assis-Ramos, M. M., Vitoretti, L. B., Couto, G. K., Rossoni, L. V., Oliveira-Filho, R. M., Vargaftig, B. B., & Tavares-de-Lima, W. (2013) · Shock · doi:10.1097/shk.0b013e3182a01e24 · Cited by 53 · see citing works
Comparative Experimental Investigation of the Anabolic Activity of Phytoecdysteroids and Steranabols
Syrov, V. N. (2000) · Pharmaceutical Chemistry Journal · doi:10.1007/bf02524596 · Cited by 53 · see citing works
β-Ecdysone has bone protective but no estrogenic effects in ovariectomized rats
Seidlova-Wuttke, D., Christel, D., Kapur, P., Nguyen, B. T., Jarry, H., & Wuttke, W. (2010) · Phytomedicine · doi:10.1016/j.phymed.2010.03.021 · Cited by 51 · see citing works
Estrogen receptor β exon 3-deleted mouse: The importance of non-ERE pathways in ERβ signaling
Maneix, L., Antonson, P., Humire, P., Rochel-Maia, S. S., Castañeda, J., Omoto, Y., Kim, H., Warner, M. N., & Gustafsson, J.-Α. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1504944112 · Cited by 51 · see citing works
Morales, M. G., Ábrigo, J., Meneses, C., Simón, F., Cisternas, F., Rivera, J. C. A., Vázquez, Y., & Cabello‐Verrugio, C. (2014) · Clinical Science · doi:10.1042/cs20130585 · Cited by 51 · see citing works
Garratt, M., Leander, D. C., Pifer, K., Bower, B., Herrera, J. J., Day, S. M., Fiehn, O., Brooks, S. V., & Miller, R. A. (2019) · Aging Cell · doi:10.1111/acel.12920 · Cited by 49 · see citing works
AVE0991, a nonpeptide analogue of Ang-(1-7), attenuates aging-related neuroinflammation
Jiang, T., Xue, L., Yang, Y., Wang, Q., Xiao, X., Ou, Z., Gao, Q., Shi, J., Wu, L., & Zhang, Y.-D. (2018) · Aging · doi:10.18632/aging.101419 · Cited by 48 · see citing works
Abrogation of ER stress-induced apoptosis of alveolar epithelial cells by angiotensin 1–7
Uhal, B. D., Nguyen, H. T. T., Dang, M., Gopallawa, I., Jiang, J., Dang, V., Ono, S., & Morimoto, K. (2013) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00001.2013 · Cited by 47 · see citing works
Nervi, C., Benedetti, L., Minasi, A., Molinaro, M., & Adamo, S. (1995) · PubMed · Cited by 46 · see citing works
GPCR-mediated rapid, non-genomic actions of steroids: Comparisons between DmDopEcR and GPER1 (GPR30)
Evans, P. D., Bayliss, A. L., & Reale, V. (2013) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2013.10.015 · Cited by 45 · see citing works
Villalobos, L. A., Hipólito‐Luengo, Á. S., Ramos-González, M., Cercas, E., Vallejo, S., Romero, A., Romacho, T., Carraro, R., Sánchez‐Ferrer, C. F., & Peiró, C. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00482 · Cited by 45 · see citing works
Mas receptor is involved in the estrogen-receptor induced nitric oxide-dependent vasorelaxation
Sobrino, A., Vallejo, S., Novella, S., Lázaro‐Franco, M., Mompeón, A., Bueno‐Betí, C., Walther, T., Sánchez‐Ferrer, C. F., Peiró, C., & Hermenegildo, C. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.01.012 · Cited by 45 · see citing works
Challenging estrogen receptor β with phosphorylation
Sanchez, M., Picard, N., Sauvé, K., & Tremblay, A. (2009) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2009.09.007 · Cited by 44 · see citing works
Ang-(1-7) treatment attenuates lipopolysaccharide-induced early pulmonary fibrosis
Cao, Y., Liu, Y., Shang, J., Yuan, Z., Feng, P., Yao, S., Guo, Y., & Li, Y. (2019) · Laboratory Investigation · doi:10.1038/s41374-019-0289-7 · Cited by 44 · see citing works
Lysophosphatidic acid mediates pleiotropic responses in skeletal muscle cells
Jean-Baptiste, G., Yang, Z., Khoury, C., & Greenwood, M. T. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.08.011 · Cited by 43 · see citing works
Steroid hormone rapid signaling: The pivotal role of S-Palmitoylation
Marino, M., & Ascenzi, P. (2006) · IUBMB Life · doi:10.1080/15216540601019485 · Cited by 43 · see citing works
Wu, C.-C., Chang, C., Chang, S., & Chen, S.-H. (2016) · Shock · doi:10.1097/shk.0000000000000586 · Cited by 40 · see citing works
AVE 0991 attenuates cardiac hypertrophy through reducing oxidative stress
Ma, Y., Huang, H., Jiang, J., Wu, L., Lin, C., Tang, A., Dai, G., He, J., & Chen, Y. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.09.050 · Cited by 38 · see citing works
He, J., Yang, Z., Yang, H., Wang, L., Wu, H.-L., Fan, Y., Wang, W., Fan, X., & Li, X. (2015) · Peptides · doi:10.1016/j.peptides.2014.12.012 · Cited by 38 · see citing works
Feldman, R. D., Ding, Q., Hussain, Y., Limbird, L. E., Pickering, J. G., & Gros, R. (2016) · The FASEB Journal · doi:10.1096/fj.15-275552 · Cited by 38 · see citing works
17β-estradiol inhibits angiotensin II-induced cardiac myofibroblast differentiation
Wu, M., Han, M., Li, J., Xu, X., Li, T., Que, L., Ha, T., Li, C., Chen, Q., & Li, Y. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.05.016 · Cited by 37 · see citing works
Zhou, L., Xue, H., Wang, Z., Ni, J., Yao, T., Huang, Y., Yu, C., & Lü, L. (2012) · Life Sciences · doi:10.1016/j.lfs.2011.12.015 · Cited by 36 · see citing works
Contribution of the Local RAS to Hematopoietic Function: A Novel Therapeutic Target
Rodgers, K. E., & diZerega, G. S. (2013) · Frontiers in Endocrinology · doi:10.3389/fendo.2013.00157 · Cited by 36 · see citing works
Kilarkaje, N., Yousif, M. H. M., El‐Hashim, A. Z., Makki, B., Akhtar, S., & Benter, I. F. (2013) · Fertility and Sterility · doi:10.1016/j.fertnstert.2013.02.046 · Cited by 35 · see citing works
Ábrigo, J., Simon, F., Cabrera, D., & Cabello-Verrugio, C. (2016) · Cellular Physiology and Biochemistry · doi:10.1159/000452522 · Cited by 35 · see citing works
Xue, F., Yang, J., Cheng, J., Sui, W., Cheng, C., Li, H., Zhang, M., Zhang, J., Xu, X., Ma, J., et al. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14906 · Cited by 35 · see citing works
Cong, B., Zhu, X., Cao, B., Xiao, J., Wang, Z., & Ni, X. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.07.231 · Cited by 34 · see citing works
Effect of a Selective Mas Receptor Agonist in Cerebral Ischemia In Vitro and In Vivo
Lee, S., Evans, M. A., Chu, H. X., Kim, H. A., Widdop, R. E., Drummond, G. R., & Sobey, C. G. (2015) · PLoS ONE · doi:10.1371/journal.pone.0142087 · Cited by 34 · see citing works
Cabello‐Verrugio, C., Rivera, J. C. A., & García, D. (2017) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000361 · Cited by 34 · see citing works
Nematbakhsh, M., Iran-Nejad, A., Eshraghi-Jazi, F., & Talebi, A. (2015) · International Journal of Preventive Medicine · doi:10.4103/2008-7802.153537 · Cited by 33 · see citing works
Cunha, T. M. B., de Lima, W. G., Silva, M. E., Santos, R. A. S., Campagnole‐Santos, M. J., & Alzamora, A. C. (2013) · Life Sciences · doi:10.1016/j.lfs.2012.12.008 · Cited by 33 · see citing works
Centrally Synthesized Estradiol Is a Potent Anti-Inflammatory in the Injured Zebra Finch Brain
Pedersen, A. L., Nelson, L. H., & Saldanha, C. J. (2016) · Endocrinology · doi:10.1210/en.2015-1991 · Cited by 33 · see citing works
Hao, P., Yang, J., Liu, Y., Zhang, M., Zhang, K., Gao, F., Chen, Y., Zhang, C., & Zhang, Y. (2015) · Scientific Reports · doi:10.1038/srep08794 · Cited by 30 · see citing works
(1983) · Hoppe-Seyler´s Zeitschrift für physiologische Chemie · doi:10.1515/bchm2.1983.364.2.1067 · Cited by 29 · see citing works
Zeng, W., Chen, W., Leng, X., Tang, L., Sun, X., Li, C., & Dai, G. (2010) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2010.00255.x · Cited by 28 · see citing works
Hamidi, S. A., Dickman, K. G., Berisha, H., & Said, S. I. (2011) · Endocrinology · doi:10.1210/en.2011-1631 · Cited by 27 · see citing works
Sundaram, R., Naresh, R., Shanthi, P., & Sachdanandam, P. (2012) · Phytomedicine · doi:10.1016/j.phymed.2012.02.019 · Cited by 27 · see citing works
20-Hydroxyecdysone Attenuates TGF-Β1-Induced Renal Cellular Fibrosis in Proximal Tubule Cells
Hung, T.-J., Chen, W.-M., Liu, S.-F., Liao, T.-N., Lee, T.-C., Chuang, L.-Y., Guh, J.-Y., Hung, C.-Y., Hung, Y.-J., Chen, P.-Y., et al. (2012) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2012.06.014 · Cited by 25 · see citing works
Suski, M., Olszanecki, R., Stachowicz, A., Madej, J., Bujak-Giżycka, B., Okoń, K., & Korbut, R. (2013) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2013.08.008 · Cited by 23 · see citing works
Assessing herbal products with health claims
Lapenna, S., Gemen, R., Wollgast, J., Worth, A., Maragkoudakis, P., & Caldeira, S. (2015) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2012.726661 · Cited by 23 · see citing works
Willey, J. S., Bracey, D. N., Gallagher, P. E., Tallant, E. A., Wiggins, W. F., Callahan, M. F., Smith, T. L., & Emory, C. L. (2016) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.o.00545 · Cited by 23 · see citing works
Xu, C., Ding, W. Q., Zhang, M., & Gu, Y. (2013) · Nephrology · doi:10.1111/nep.12146 · Cited by 22 · see citing works
Pawlik, M., Kwiecień, S., Ptak‐Belowska, A., Pajdo, R., Olszanecki, R., Suski, M., Madej, J., Targosz, A., Konturek, S. J., Korbut, R., et al. (2016) · PubMed · Cited by 22 · see citing works
Angiotensin (1–7) protects against stress-induced gastric lesions in rats
Zhu, D., Tong, Q., Liu, W., Tian, M., Xie, W., Li, J., & Shi, J. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.10.026 · Cited by 21 · see citing works
The effects of 20-hydroxyecdysone and 17β-estradiol on the skin of ovariectomized rats
Ehrhardt, C., Wessels, J. T., Wuttke, W., & Seidlová-Wuttke, D. (2011) · Menopause · doi:10.1097/gme.0b013e3181f322e3 · Cited by 20 · see citing works
He, J., Chen, S., Huang, Y., Chen, Y., Dong, Y., & Ma, H. (2010) · Heart and Vessels · doi:10.1007/s00380-009-1213-7 · Cited by 20 · see citing works
17β-estradiol ameliorates oxygen-induced retinopathy in the early hyperoxic phase
Zhang, H., Wang, X., Xu, K., Wang, Y., Wang, Y., Liu, X., Zhang, X., Wang, L., & Li, X. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.01.052 · Cited by 20 · see citing works
Jawień, J., Totoń‐Żurańska, J., Kuś, K., Pawlowska, M., Olszanecki, R., & Korbut, R. (2012) · Medical Science Monitor · doi:10.12659/msm.883478 · Cited by 19 · see citing works
Pastore, M. B., Landeros, R. V., Chen, D., & Magness, R. R. (2018) · Biology of Reproduction · doi:10.1093/biolre/ioy188 · Cited by 19 · see citing works
Cong, B., Xu, Y., Sheng, H., Zhu, X., Wang, L., Zhao, W., Tang, Z., Lu, J., & Ni, X. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.09.002 · Cited by 18 · see citing works
N-terminal truncations in sex steroid receptors and rapid steroid actions
Schreihofer, D. A., Duong, P., & Cunningham, R. L. (2017) · Steroids · doi:10.1016/j.steroids.2017.10.018 · Cited by 18 · see citing works
Du, D., Ma, X., Zhang, J., Zhang, Y., Zhou, X., & Yu, L. (2009) · Life Sciences · doi:10.1016/j.lfs.2009.11.001 · Cited by 17 · see citing works
Synthesis and biological activities of turkesterone 11α-acyl derivatives
Dinan, L. N., Bourne, P. C., Whiting, P., Tsitsekli, A., Saatov, Z., Dhadialla, T. S., Hormann, R. E., Lafont, R., & Coll, J. (2003) · Journal of Insect Science · doi:10.1093/jis/3.1.6 · Cited by 16 · see citing works
Self-citationβ-Ecdysone Augments Peak Bone Mass in Mice of Both Sexes
Dai, W., Zhang, H., Zhong, Z. A., Jiang, L., Chen, H., Lay, Y.-A. E., Kot, A., Ritchie, R. O., Lane, N. E., & Yao, W. (2015) · Clinical Orthopaedics & Related Research · doi:10.1007/s11999-015-4246-5 · Cited by 15 · see citing works
Syrov, V. N., Nasyrova, S. S., & Khushbaktova, Z. A. (1997) · PubMed · Cited by 14 · see citing works
Pharmacology of doping agents—mechanisms promoting muscle hypertrophy
Parr, M. K., & Laughlin, A. M. M. (2018) · AIMS molecular science · doi:10.3934/molsci.2018.2.131 · Cited by 13 · see citing works
Mykhaylyk, O. M., Kotzuruba, A. V., Buchanevich, O. M., Korduban, A. M., Meged, E. F., & Gulaya, N. M. (2001) · Journal of Magnetism and Magnetic Materials · doi:10.1016/s0304-8853(00)01262-2 · Cited by 12 · see citing works
Shakhmurova, G. A., Syrov, V. N., & Khushbaktova, Z. A. (2010) · Pharmaceutical Chemistry Journal · doi:10.1007/s11094-010-0387-8 · Cited by 12 · see citing works
Sundaram, R., Rajendran, N. K., Shanthi, P., & Sachdanandam, P. (2012) · Process Biochemistry · doi:10.1016/j.procbio.2012.07.025 · Cited by 12 · see citing works
Kurmukov, A. G., & Oa, E. (1991) · PubMed · Cited by 12 · see citing works
Gorelick-Feldman, J. (2009) · Rutgers University Community Repository (Rutgers University) · doi:10.7282/t3wq041h · Cited by 10 · see citing works
Angiotensin-(1–7) synergizes with colony-stimulating factors in hematopoietic recovery
Rodgers, K. E., Espinoza, T. B., Roda, N., Meeks, C. J., & diZerega, G. S. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2312-9 · Cited by 10 · see citing works
Zubeldia, J. M., Hernández-Santana, A., Jiménez-del-Rio, M., Pérez-López, V., Pérez-Machín, R., & García-Castellano, J. M. (2012) · Chinese Medicine · doi:10.4236/cm.2012.34031 · Cited by 9 · see citing works
Korkach, I. P., Kotsiuruba, A. V., Prysiazhna, O. D., Ld, M., & Vf, S. (2007) · PubMed · Cited by 9 · see citing works
Angiotensin-Converting Enzyme 2/Angiotensin-(1-7)/Mas Receptor Axis
Shenoy, V., Ferreira, A. J., Katovich, M. J., & Raizada, M. K. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-801364-9.00038-9 · Cited by 8 · see citing works
Crustecdysone is without estrogenic or antiestrogenic activity in the rat
Prabhu, V. K. K., & Nayar, K. K. (1974) · Experientia · doi:10.1007/bf01924207 · Cited by 8 · see citing works
Hoffmann, J. A., & Weins, M.-J. (1974) · Cellular and Molecular Life Sciences · doi:10.1007/bf01924208 · Cited by 8 · see citing works
Ajuga Turkestanica as a Countermeasure Against Sarcopenia and Dynapenia
Lawrence, M. M. (2014) · NC Digital Online Collection of Knowledge and Scholarship (The University of North Carolina at Greensboro) · doi:10.71889/5fylantbak.29860187 · Cited by 6 · see citing works
Tipbunjong, C., Kitiyanant, Y., Chaturapanich, G., Sornkaew, N., Suksamrarn, A., Kitiyanant, N., Esser, K. A., & Pholpramool, C. (2016) · Medicinal Chemistry Research · doi:10.1007/s00044-016-1748-y · Cited by 6 · see citing works
Tipbunjong, C., Khuituan, P., Kitiyanant, Y., Suksamrarn, A., & Pholpramool, C. (2019) · Journal of Natural Medicines · doi:10.1007/s11418-019-01322-7 · Cited by 6 · see citing works
Yadav, S. K., Reddy, B. V. K., & Sharma, P. (2013) · Cited by 3 · see citing works
The relationship between proteinuria and cardiovascular disease: a systematic review
Perkovic, V., Ninomiya, T., Verdon, C., Barzi, F., Cass, A., Craig, J. C., Jardine, M., Gallagher, M., Chalmers, J. P., & Huxley, R. (2009) · Deakin Research Online (Deakin University) · Cited by 3 · see citing works
Effect of Ecdysterone on the Healing of Gastric Ulcer in Model Rats
Zhang, Z., & Liao, J. (2010) · Zhongguo yaofang · Cited by 3 · see citing works
Wuttke, W., & Seidlová‐Wuttke, D. (2015) · Journal für Kardiologie (Krause & Pachernegg GmbH) · Cited by 2 · see citing works
Sobrino, A., Novella, S., Monsalve, E., Oviedo, P., Laguna-Fernández, A., Bueno, C., & Hermenegildo, C. (2010) · Journal of Hypertension · doi:10.1097/01.hjh.0000379388.11921.88 · Cited by 2 · see citing works
Effect of ecdysterone on the nervous lesions of rabbits acquired after subarachnoid hemorrhage
Hu, F. (2011) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 2 · see citing works
Influence of angiotensin-(1–7) peptidemimetic (AVE 0991) on liver mitoproteome in apoE-knockout mice
Suski, M., Olszanecki, R., Bujak-Giżycka, B., Madej, J., Stachowicz, A., & Korbut, R. (2012) · Vascular Pharmacology · doi:10.1016/j.vph.2011.08.213 · Cited by 2 · see citing works
Role of 20-hydroxyecdysone in protecting rats against diabetic cardiomyopathy
Liang, G. (2013) · Zhonghua laonian xin-nao-xueguanbing zazhi · Cited by 2 · see citing works
Kotsiuruba, A. V., Bukhanevych, O. M., Ah, B., Mehed', O. F., Hula, N. M., Mykhaĭlik, O. M., & Bakaĭ, E. A. (1998) · PubMed · Cited by 2 · see citing works
Barroso, L. C., da Silveira, K. D., Teixeira, M. M., & Silva, A. C. S. E. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-801364-9.00030-4 · Cited by 2 · see citing works
Santos, R. A. S., & Sampaio, W. O. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-801364-9.00027-4 · Cited by 1 · see citing works
Chodavarapu, H., & Lazartigues, E. D. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-801364-9.00031-6 · Cited by 1 · see citing works
Hermenegildo, C., Sobrino, A., Monsalve, E., Bueno‐Betí, C., Laguna-Fernández, A., Sánchez‐Ferrer, C. F., Peiró, C., & Novella, S. (2011) · Journal of Hypertension · doi:10.1097/00004872-201106001-00157 · Cited by 1 · see citing works
Mas and Neuroprotection in Stroke
Bennion, D. M., Regenhardt, R. W., Mecca, A. P., & Sumners, C. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-801364-9.00028-6 · Cited by 1 · see citing works
Flagged first, then by citations
2 of the 166 references couldn’t be matched to a known paper.
Research works printed but not linked: 25
- 1988, Combined application of preparation Ecdysten and product Bodrost during training in cyclic sports, Scientific Sports Bulletin, 2, 29
- 1995, Mechanisms of the early effect of biologically active oxysterones calcitriol and ecdysterone, modulation of intracellular pools of arachidonic acid and products of its oxidative metabolism, Ukrainian Biokhim Zhurnal, 67, 45
- 1999, The C(27)-steroid hormones ecdysterone and calcitriol activate the phosphoinositide messenger cascade in its membrane phase of action, Ukrainian Biokhim Zhurnal, 71, 27
- 1988, Effects of methandrostenolone and ecdysterone on physical endurance of animals and protein metabolism in the skeletal muscles, Farmakol Toksikol, 6, 57
- 2012, Quinoa extract enriched in 20-hydroxyecdysone protects mice from diet-induced obesity and modulates adipokines expression, Obesity, 20, 270, 10.1038/oby.2011.257 · DOI · Paper page
- 2008, β-Ecdysterone induces osteogenic differentiation in mouse mesenchymal stem cells and relieves osteoporosis, Biol Pharm Bull, 31, 2245, 10.1248/bpb.31.2245 · DOI · Paper page
- 2010, Ecdysteroids elicit a rapid Ca2+ flux leading to Akt activation and increased protein synthesis in skeletal muscle cells, Steroids, 70, 632
- 10.1152/ajpendo.90772.2008 · DOI · Paper page
- 10.1161/circresaha.113.301077 · DOI
- 2013, Effect of ecdysterone on the expression of toll-like receptor 4 and surfactant protein A in lung tissue of rats with acute lung injury, Infect Inframm Rep, 14, 22
- 2009, Effect of ecdysterone on injury of lipid peroxidation following focal cerebral ischemia in rats, Zhongguo Yaoye, 18, 12
- 10.1002/mnfr.201300806 · DOI · Paper page
- 10.5604/20831862.1144420 · DOI · Paper page
- 2009, Cardiac anti-fibrotic effects of angiotensin (1-7) effects of angiotensin (1-7) mimetic in aged mice, Hypertension, 53, 1116
- 2010, β-Ecdysone has bone protective but no estrogenic effects in ovariectomized rats, Phytomedicine, 17, 884, 10.1016/j.phymed.2010.03.021 · DOI · Paper page
- 2010, The administration of the agonist of angiotensin-(1-7), AVE0991, improved inflammation and proteinuria in experimental nephrotic syndrome, Pediatr Nephrol, 25, 1795
- 2012, Possible mechanism of the cardio-renal effects of AVE-0991, a nonpeptide Mas-receptor agonist, in diabetic rats, JRAAS, 13, 334
- 2017, Mas receptor is involved in the estrogen-receptor induced nitric oxide-dependent vasorelaxation, Biochemical Pharmacology, 129, 67, 10.1016/j.bcp.2017.01.012 · DOI
- 2019, Protective effect of 20-hydroxyecdysone against lipopolysaccharides-induced acute lung injury in mice, Journal of Pharmaceutics and Drug Research, 2, 109
- 1992, An experimental study of the hepatoprotective properties of phytoecdysteroids and nerobol in carbon tetrachloride - induced liver injury, Eksp Klin Farmakologiya, 55, 61
- Tchoukouegno Ngueu S. 2013. Bioactivity of plant secondary metabolites. Estrogenic, cytotoxic and anabolic effects on estrogen target organs of an extract of Erythrinaexcelsa and ecdysterone. PhD Thesis, Univ Cologne.
- 10.1096/fj.11-194779 · DOI · Paper page
- 1998, Effects of ecdysterone on rat lung reperfusion injury, Zhongguo Yaolixue Tongbao (Chinese Pharmaceutical Bulletin), 14, 256
- 2013, Protective effect of 20-hydroxyecdysone on diabetic hepathopathy of rats, Xiandai Yufang Yixue, 40, 4031
- 2010, Effects of ecdysterone on early stage diabetic nephropathy in streptozotocin-induced diabetic rats, Zhongguo Xinyao Yu Lingchuan Zazhi, 29, 842
Cited by
Sorted by citations
Dinan, L., Dioh, W., Veillet, S., & Lafont, R. (2021) · Biomedicines · doi:10.3390/biomedicines9050492 · Cited by 99 · see citing works
“Further experiments with C2C12 cells [113] indicate that the two hypotheses for the mode of action of 20E on these cells might be unified.”
InfluentialSelf-citationAdvances in research on pharmacotherapy of sarcopenia
Feike, Y., Liu, Z., & Chen, W. (2021) · Aging Medicine · doi:10.1002/agm2.12168 · Cited by 67 · see citing works
Lafont, R., Balducci, C., & Dinan, L. (2021) · Encyclopedia · doi:10.3390/encyclopedia1040096 · Cited by 49 · see citing works
Self-citationBalkrishna, A., Khandrika, L., & Varshney, A. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.635510 · Cited by 47 · see citing works
Latil, M., Camelo, S., Veillet, S., Lafont, R., & Dilda, P. J. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.02.010 · Cited by 31 · see citing works
Self-citationGaur, P. K., Rastogi, S., & Lata, K. (2022) · Phytomedicine Plus · doi:10.1016/j.phyplu.2022.100260 · Cited by 30 · see citing works
Shuvalov, O., Kirdeeva, Y., Fefilova, E., Netsvetay, S., Zorin, M., Vlasova, Y., Fedorova, O., Daks, A., Parfenyev, S., & Barlev, N. (2023) · Metabolites · doi:10.3390/metabo13050656 · Cited by 21 · see citing works
“The same phenomenon has been reported by other authors in different biological systems [88,89].”
BackgroundCamelo, S., Latil, M., Agus, S., Dioh, W., Veillet, S., Lafont, R., & Dilda, P. J. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.2006579 · Cited by 9 · see citing works
Self-citationIssaadi, H. M., Béni, Z., Tóth, T., Dékány, M., Hsieh, T., Balogh, G. T., & Hunyadi, A. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.104951 · Cited by 6 · see citing works
“the G-protein-coupled receptor of angiotensin-(1–7) [51].”
BackgroundGiloy: a potential anti-COVID-19 herb with propitious pharmacological attributes: a short review
Arora, S., Goyal, A., Rawat, D. S., & Samantha, K. (2022) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2022.2110157 · Cited by 1 · see citing works
“…(b-ecdysone) to induce osteogenic transformation (Abiramasundari et al., 2018). b-ecdysone showed good immunomodulatory activity with favorable Renin-Angiotensin system (LaFont et al., 2020) which in turn is very advantageous in the infection of SARCoV-2 infection as the ACE-2 receptor.”
Влияние 20-гидроксиэкдизона на медоносную пчелу в условиях теплового стресса
Викторович, А. Н. (2024) · Perm Scientific Center Journal · doi:10.7242/2658-705x/2024.1.4
- Authors
- Lafont, R., Raynal, S., Serova, M., Didry-Barca, B., Guibout, L., Latil, M., Dilda, P. J., Dioh, W., & Veillet, S.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- Sorbonne Université (FR)
- Corresponding author
- Dilda, Pierre J.
- ORCID
- Venue
- bioRxiv (Cold Spring Harbor Laboratory)
- Publisher
- openRxiv
- Published
- 2020-04-10
- OpenAlex
- W3015408723
- Semantic Scholar
- f2100f9f463075176a3a31e3f6639901c5b9cbad
- Cited by
- 11
- References
- 166
- Citations by year
- 2024: 1 · 2023: 1 · 2022: 2 · 2021: 7
- Type
- posted content
- Language
- en
- Open access
- green
- doi.org
- Locations
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
- Funders
- Université de Bordeaux
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Estrogen and related hormone effects
- Keywords
- 20-hydroxyecdysone, ecdysteroids, Mas receptor, angiotensin-(1-7), renin-angiotensin system, myostatin, estrogen receptor beta, muscle growth, C2C12 myoblasts
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Claims read by deepseek-v4.1-flash under definition version 3 (extract-v3) on 2026-10-10.
Classified by jev-1.13-20260917 (gold-guideline-v0.2) on 2026-10-10.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
